ReviewDermatology and therapy2021
Light-Based Devices for the Treatment of Facial Erythema and Telangiectasia.
Review in Dermatology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Combined 595-nm pulsed dye laser and picosecond laser toning for the treatment of extensive erythema ab igne: A case report.JAAD case reports · 2026Article
- Photothermal interaction of a 1927 nm Thulium laser with MatriDerm: an in vitro study.Lasers in medical science · 2026Article
- Post-inflammatory Hyperpigmentation in Skin of Color: Emerging Therapies and Treatment Algorithms.Cureus · 2026Review
- Laser-Based Therapies in Rosacea: A Comprehensive Review of Mechanisms, Clinical Efficacy, and Future Directions.Journal of clinical medicine · 2026Review
- Aesthetic Treatment Considerations in Patients with Cutaneous Autoimmune Disease.The Journal of clinical and aesthetic dermatology · 2025Review
- Potential of neodymium laser in treatment of extensive telangiectasias on the face.Lasers in medical science · 2025Article
- Efficacy and prognostic factors for successful treatment of port-wine stains by 577-nm yellow laser: a cohort study on 42 patients.Lasers in medical science · 2025Article
- Methods of Quantitative Assessment of the Response of Dilated Skin Blood Vessels to High-Energy Light Treatments.Journal of clinical medicine · 2024Article
- Effective Treatment of Rosacea and Other Vascular Lesions Using Intense Pulsed Light System Emitting Vascular Chromophore-Specific Wavelengths: A Clinical and Dermoscopical Analysis.Journal of clinical medicine · 2024Article
- A Review of the Diagnostic and Therapeutic Gaps in Rosacea Management: Consensus Opinion.Dermatology and therapy · 2024Article
- Effect of Topical Platelet Extract Daily Serum as a Cosmetic Product to Reduce Facial Redness.The Journal of clinical and aesthetic dermatology · 2023Article
- Narrowband Intense Pulsed Light Treatment for Refractory Facial Rash Associated with Dermatomyositis.Clinical, cosmetic and investigational dermatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Facial erythema is one of the most common outpatient complaints in dermatology. There are various causes of facial erythema and several devices are available for its treatment. Pulsed dye laser (PDL) and intense pulsed light (IPL) are the two common light devices used for these conditions. In this review, we evaluated the literature to assess efficacy of IPL versus PDL in facial erythema and telangiectasia. We searched published articles including clinical trials or reviews articles, case series, and case reports. Electronic databases (MEDLINE and PubMed) were searched to retrieve the articles. Reference lists of selected articles were also considered for the review. Articles published in English language until June 2021 were considered for this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.